关于人类癌症中的免疫监视
On immunosurveillance in human cancer.
作者信息
Thomas L
出版信息
Yale J Biol Med. 1982 May-Aug;55(3-4):329-33.
Abstract
The extraordinarily high incidence of cancers of many different varieties--carcinomas and lymphomas--in organ-transplant patients being maintained for long periods of time with immunosuppressive drugs is briefly reviewed. The role of immunosurveillance as a primary defense mechanism against cancer in human beings is consistent with these observations and is in need of further investigation. Conceivably, this mechanism may play a somewhat different role in humans from what has been observed in most experimental animal models.
摘要
简要回顾了长期使用免疫抑制药物维持治疗的器官移植患者中多种不同类型癌症（癌和淋巴瘤）的极高发病率。免疫监视作为人类抵御癌症的主要防御机制，这一作用与这些观察结果相符，且有待进一步研究。可以想象，该机制在人类中可能发挥的作用与大多数实验动物模型中所观察到的有所不同。
相似文献
1
On immunosurveillance in human cancer.关于人类癌症中的免疫监视
Yale J Biol Med. 1982 May-Aug;55(3-4):329-33.
2
[Immunosuppression mechanism affecting the development of neoplasms].影响肿瘤发生发展的免疫抑制机制
Pol Tyg Lek. 1980 Mar 24;35(12):455-7.
3
Introduction: Modification of immunity and carcinogenesis.引言：免疫与致癌作用的改变。
Natl Cancer Inst Monogr. 1972 Dec;35:149-56.
4
5
Clinical and dermatoscopic fading of post-transplant eruptive melanocytic nevi after suspension of immunosuppressive therapy.免疫抑制治疗中断后移植后爆发性黑素细胞痣的临床及皮肤镜消退情况
J Am Acad Dermatol. 2006 Feb;54(2):338-40. doi: 10.1016/j.jaad.2005.06.023.
6
[Immunoreactivity in tumor growth].[肿瘤生长中的免疫反应性]
Vopr Onkol. 1987;33(4):99-106.
7
Immunosurveillance and cancer: epidemiologic observations.免疫监视与癌症：流行病学观察
Natl Cancer Inst Monogr. 1977 Dec;47:121-6.
8
Immunoregulatory T cells in tumor immunity.肿瘤免疫中的免疫调节性T细胞。
Curr Opin Immunol. 2004 Apr;16(2):157-62. doi: 10.1016/j.coi.2004.01.010.
9
Role of major histocompatibility complex in genetic regulation of immunologic responsiveness.主要组织相容性复合体在免疫反应性基因调控中的作用。
Transplant Proc. 1977 Mar;9(1):825-31.
10
[Frontier of mycobacterium research--host vs. mycobacterium].[分枝杆菌研究前沿——宿主与分枝杆菌]
Kekkaku. 2005 Sep;80(9):613-29.
引用本文的文献
1
Optimal Control of Immune Checkpoint Inhibitor Therapy in a Heart-Tumour Model.心脏肿瘤模型中免疫检查点抑制剂治疗的最优控制
Bull Math Biol. 2025 Aug 11;87(9):127. doi: 10.1007/s11538-025-01468-4.
2
From concept to cure: The evolution of CAR-T cell therapy.从概念到治愈：嵌合抗原受体T细胞疗法的演变
Mol Ther. 2025 May 7;33(5):2123-2140. doi: 10.1016/j.ymthe.2025.03.005. Epub 2025 Mar 10.
3
The evolution of cancer immunotherapy: a comprehensive review of its history and current perspectives.癌症免疫疗法的演变：对其历史和当前观点的全面综述。
Korean J Clin Oncol. 2024 Dec;20(2):51-73. doi: 10.14216/kjco.24009. Epub 2024 Dec 31.
4
Coley's Toxin to First Approved Therapeutic Vaccine-A Brief Historical Account in the Progression of Immunobiology-Based Cancer Treatment.科利毒素到首个获批的治疗性疫苗——基于免疫生物学的癌症治疗进展简史
Biomedicines. 2024 Nov 30;12(12):2746. doi: 10.3390/biomedicines12122746.
5
Antagonistic roles of cGAS/STING signaling in colorectal cancer chemotherapy.cGAS/STING信号通路在结直肠癌化疗中的拮抗作用
Front Oncol. 2024 Oct 14;14:1441935. doi: 10.3389/fonc.2024.1441935. eCollection 2024.
6
Advancements and Challenges in Peptide-Based Cancer Vaccination: A Multidisciplinary Perspective.基于肽的癌症疫苗接种的进展与挑战：多学科视角
Vaccines (Basel). 2024 Aug 22;12(8):950. doi: 10.3390/vaccines12080950.
7
The effect of gD-derived peptides on T cell immune response mediated by BTLA-HVEM protein complex in melanoma patients.gD 衍生肽对黑色素瘤患者 BTLA-HVEM 蛋白复合物介导的 T 细胞免疫反应的影响。
Front Immunol. 2024 May 21;15:1362152. doi: 10.3389/fimmu.2024.1362152. eCollection 2024.
8
Modulatory Role of Phytochemicals/Natural Products in Cancer Immunotherapy.植物化学物质/天然产物在癌症免疫治疗中的调节作用。
Curr Med Chem. 2024;31(32):5165-5177. doi: 10.2174/0109298673274796240116105555.
9
An immunogenetic basis for lung cancer risk.肺癌风险的免疫遗传学基础。
Science. 2024 Feb 23;383(6685):eadi3808. doi: 10.1126/science.adi3808.
10
Establishment of immune suppression by cancer cells in the tumor microenvironment.肿瘤微环境中癌细胞的免疫抑制建立。
Proc Jpn Acad Ser B Phys Biol Sci. 2024;100(2):114-122. doi: 10.2183/pjab.100.005.
本文引用的文献
1
Cancer following successful cadaveric donor renal transplantation.
Transplant Proc. 1981 Mar;13(1 Pt 2):733-5.
2
Kaposi's sarcoma after kidney transplantation. Report of complete remission of cutaneous and visceral involvement.
Transplantation. 1980 Nov;30(5):383-4. doi: 10.1097/00007890-198011000-00016.
3
Reactivation of ocular malignant melanoma after renal transplantation.
Transplantation. 1980 May;29(5):421-4. doi: 10.1097/00007890-198005000-00017.
4
Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells.环磷酰胺辅助的已建立肿瘤的过继性免疫疗法取决于肿瘤诱导的抑制性T细胞的清除。
J Exp Med. 1982 Apr 1;155(4):1063-74. doi: 10.1084/jem.155.4.1063.
5
Cyclosporin A.环孢素A
Transplantation. 1981 Nov;32(5):349-54.
6
Immunologic approaches to the management of primary and secondary tumors involving the skin and soft tissues: review of a ten-year program.
Transplant Proc. 1975 Jun;7(2):297-315.
7
Multiple primary cancers of the lung, esophagus, and other sites.
Cancer. 1977 Oct;40(4 Suppl):1954-60. doi: 10.1002/1097-0142(197710)40:4+<1954::aid-cncr2820400830>3.0.co;2-b.
8
Non-adaptive rejection of small tumour inocula as a model of immune surveillance.将小肿瘤接种物的非适应性排斥作为免疫监视模型
Nature. 1976 Nov 25;264(5584):356-9. doi: 10.1038/264356a0.
9
Malignant neoplasms following cardiac transplantation.
JAMA. 1978 Aug 18;240(7):639-43.
10
Development of cancer as a complication of clinical transplantation.
Transplant Proc. 1977 Mar;9(1):1121-7.
Zotero 插件